ADVERTISEMENT

Lymphoma, Myeloma & Prostate Cancer

FDA approves Mozobil for non-Hodgkin lymphoma and myeloma, and Degarelix for advanced prostate cancer. 

BY ELIZABETH WHITTINGTON
PUBLISHED FRIDAY, MARCH 13, 2009
Talk about this article with other patients, caregivers, and advocates in the Myeloma CURE discussion group.
The Food and Drug Administration approved Mozobil (plerixafor) in December for patients with non-Hodgkin lymphoma and multiple myeloma who are undergoing a stem cell transplant. The injectable drug, given in combination with a growth factor called granulocyte-colony stimulating factor (G-CSF), boosts the number of stem cells in the blood, where they can be collected for transplantation.

In autologous stem cell transplantation, a patient’s stem cells are collected (called apheresis) before high-dose chemotherapy and/or radiation. The high-dose therapy kills cancer cells, but also destroys stem cells that develop into other blood cells. To counter this effect, patients are reinfused with the collected stem cells.

Typically, apheresis requires up to four hours over several days, but Mozobil appears to make the process faster and more successful. A study involving NHL patients found that in up to four apheresis attempts, 59 percent of patients taking G-CSF plus Mozobil had successful stem cell collections compared with 20 percent of patients receiving only G-CSF. Results were similar in a study with multiple myeloma patients. Adding Mozobil allowed patients to reach an adequate number of collected stem cells in a median of one day compared with four days using G-CSF alone. Side effects of Mozobil include fatigue, nausea, and diarrhea.

For more information, visit www.mozobil.com or call 877-466-9624 (site is owned by Genzyme, maker of Mozobil).

Degarelix, a type of hormonal therapy, was approved by the Food and Drug Administration for advanced hormone-dependent prostate cancer at the end of December. At press time, possible trade names were still being reviewed by the FDA.

Degarelix, an injectable gonadotrophin-releasing hormone (GnRH) blocker, reduces levels of testosterone, a hormone produced by the testes and adrenal glands that can drive the growth of some prostate cancers. This has been shown to lower prostate-specific antigen, a measure of the amount of prostate cancer.

The FDA based its approval on phase III studies that compared degarelix with another GnRH blocker called Lupron (leuprolide), a standard treatment for advanced prostate cancer. Degarelix came out on top in the studies, primarily because of the drug’s unique mechanism of action.

Degarelix works by binding to the receptors of the brain’s pituitary cells, blocking the production of luteinizing hormone (a hormone that stimulates the testes to produce testosterone). Patients taking degarelix do not experience the initial “flare” of hormone levels (and possible cancer growth) that is seen with other GnRH blockers such as Lupron.

Phase III studies have confirmed that degarelix suppresses testosterone levels and PSA faster than Lupron without causing the initial hormone flare and cancer growth. In a phase III study published in the British Journal of Urology International, 95 percent of patients taking degarelix achieved complete testosterone suppression on the third day of treatment compared with zero percent of patients taking Lupron. After two weeks, nearly 100 percent of degarelix patients had hormone suppression, while only 18 percent of patients on Lupron reached a comparable level.

Common side effects of degarelix, such as fatigue, weight gain, and hot flashes, were comparable to Lupron, although degarelix was associated with more injection-site skin reactions. For more information, visit www.prostatecancerliving.com (site is owned by Ferring Pharmaceuticals, maker of degarelix). 

Talk about this article with other patients, caregivers, and advocates in the Myeloma CURE discussion group.
ADVERTISEMENT
ShareYourStory
Related Articles
Combined Imaging Approach Effective in Detecting Aggressive Prostate Cancer
BY TONY BERBERABE, MPH
The combination of multiparametric MRI with a fusion-guided biopsy (MRI plus ultrasound) was more effective at detecting aggressive prostate cancer compared with either procedure alone.
Robotic Surgery for Prostate Cancer has Lesser Impact on Sexual Function
BY TONY BERBERABE, MPH
Although use of robotic surgery for prostate cancer has surpassed open surgical procedures in number, the impact of this approach on patient quality of life has not been well-studied.
Combo With Elotuzumab Delays Disease Progression in Myeloma
BY JASON M. BRODERICK
Adding elotuzumab to Revlimid (lenalidomide) and dexamethasone reduced the risk of disease progression by 30 percent in patients with relapsed/refractory multiple myeloma.
New Study Further Clarifies Role of Chemotherapy in Prostate Cancer
BY ANDREW J. ROTH
The addition of docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer.
Telephone Intervention Reduces Unplanned Hospital Visits for Patients With Blood Cancers
BY LAUREN M. GREEN
A navigator-designed, proactive, weekly, telephone support call to help patients with blood cancers manage their symptoms between appointments was able to significantly reduce unplanned hospitalizations at a Colorado cancer center.
Related Videos
Dr. Shore Provides an Overview of Biomarkers in Prostate Cancer
BY NEAL D. SHORE, MD, FACS
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, provides an overview of biomarkers in prostate cancer.
Jasmine Martin Discusses Oral Adherence
BY JASMINE MARTIN
Jasmine Martin, Director, West Region Medical Science Liaison Team, Takeda Oncology, discusses oral adherence.
Sandra Spoelstra, PhD, RN, on Educating Patients About Oral Agents
BY SANDRA SPOELSTRA, PHD, RN
Sandra Spoelstra, PhD, RN, Assistant Professor, College of Nursing, Michigan State University, discusses educating patients about oral agents.
Amanda Yopp, NP, Discusses Patient Education Regarding Clinical Trials
BY AMANDA YOPP, NP
Amanda Yopp, NP, Clinical Nurse Educator, Takeda Oncology, discusses educating patients before they enroll on a clinic trial.
Surgery Versus Radiation in Prostate Cancer
Surgery has its side effects, says radiation oncologist Richard Stock, including possible incontinence and sexual dysfunction. While radiation is less invasive, it does have its own side effects.
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
$auto_registration$